top of page

Sonoma Biotherapeutics announced early clinical data today in a late-breaker at #ACR25 for its CAR-Treg to treat rheumatoid arthritis. Co-Founders Jeff Bluestone and Fred Ramsdell walk us through it | 10/29/25

TOP VIDEO: Co-Founders Jeff Bluestone and Fred Ramsdell walk us through Sonoma's CAR-Treg data at #ACR25. | 10/29/25

Quick Takes

Upcoming Events

November 3-5 - BIO-Europe 2025 | Vienna, Austria

November 6 - Oppenheimer Oncology Summit at University of Miami Sylvester | Miami, FL

November 7-9 - SITC Annual Meeting | National Harbour, MD

November 11-12 - Stifel Healthcare Conference | New York, NY

November 17-19 - Jefferies Global Healthcare Conference | London, UK

December 5-9 - ASH Annual Meeting | Orlando, FL

Science Spotlight
with Chloe Kirk

AI News with Ryan Flinn

11/18/25 - Catching up with Roivant CEO Matt Gline at the Jefferies Global Healthcare Conference in London.

11/18/25 - GSK's chief scientist describes what excites him today and offers advice to young scientists.

11/17/25 - Sofinnova Partners announced a new $750 million fund to invest in early stage companies.

Latest Videos

Jefferies London: Ipsen has done a string of deals over recent years, including acquiring ImCheck last month. CEO David Loew says the company has billions in firepower to do more

Jefferies London:

Ipsen has done a string of deals over recent years. CEO David Loew says the company has billions in firepower to do more.

11/19/2025

Stephenson Harwood lawyers discuss the keys to success for deal and partnering negotiations at London Life Science Week and beyond | 11/18/25

Stephenson Harwood:
Stephenson Harwood lawyers discuss the keys to success for deal and partnering negotiations

Sponsored

Jefferies London: Terns' CEO Amy Burroughs previews the company's upcoming ASH presentation for the allosteric BCR::ABL1 inhibitor tern-701 in relapsed/refractory cml | 11/19/25

Jefferies London:

Terns' CEO previews the company's upcoming ASH presentation for the allosteric BCR::ABL1 inhibitor tern-701 in relapsed/refractory cml

11/19/2025

Jefferies London: Affinity Asset Advisors' Patrick Nosker shares a public investor's perspective on biotech and walks us through a few of his firm's top positions | 11/19/25

Jefferies London:

Affinity Asset Advisors' Patrick Nosker shares a public investor's perspective on biotech

11/19/2025

Jefferies London: Medicxi Announced a €500 Million Fund V ahead of this week's conference - Co-founder Giovanni Mariggi describes the firm's asset-centric approach to investing in biotech | 11/19/25

Jefferies London:

Medicxi announced a €500 million Fund V ahead of this week's conference

11/19//2025

Shows

Around Kendall Square

What's new at BiotechTV - from our founder

SF Healthcare Week: Nicole Paulk shares an update on her company Siren Biotechnology and describes what the environment is like for smaller companies in biotech right now | 01/16/25

09:50

SF Healthcare Week: Chris Gibson talks the Exscientia merger, Recursion's scale and capabilities, and key targets | 01/15/25

12:06

SF Healthcare Week: Rachel Haurwitz shares an update on Caribou Biosciences' allo CAR-T programs in NHL, BCMA, and lupus programs | 01/15/25

11:05

SF Healthcare Week: Affinity Asset Advisors' Head of Research Patrick Nosker shares his take on Monday's conference news, and discusses some of his fund's top holdings | 01/13/25

09:45

SF Healthcare Week: The CEO of Arvians talks protein degradation, including about the industry's first phase 3 readout that is upcoming | 01/15/25

11:42

SF Healthcare Week: Cytokinetics CEO Robert Blum describes preparing for the potential commercial launch of aficamten, an upcoming monotherapy trial readout, omecamtiv mecarbil, and more | 01/16/25

19:05

SF Healthcare Week: Baird's Brian Skorney shares his take on this morning's conference news, the year ahead, and his top picks | 01/14/24

12:13

SF Healthcare Week: Flagship Pioneering's Noubar Afeyan on Moderna, gov't policy, China, and "polyintelligence" in drug development | 01/13/25

15:58

2025 SF Healthcare Week

ASCO25: Gilead Sciences Chairman & CEO Dan O'Day discusses today's 'practice changing' data for Trodelvy in 1L triple-negative breast cancer, cell therapy, and more in the oncology pipeline | 05/31/25

15:21

ASCO 2025: Bicara Therapeutics' CEO Claire Mazumdar discusses the company's EGFR x TGF-β data in head and neck cancer, and compares and contrasts it with a closely watched competitor | 06/01/25

09:08

Pfizer Chairman & CEO Dr. Albert Bourla discusses the company's bets on cancer research, VEGF x PD1, #ASCO25 data, and hot button issues affecting the biopharma industry | 05/30/25

19:01

ASCO 2025: Instil Bio CEO Bronson Crouch discusses the company's PD1 x VEGF, and shares a quick take on this morning's competitor news | 05/30/25

09:58

ASCO 2025: Gilead Sciences' Chairman & CEO Dan O'Day discusses today's 'practice changing' data for Trodelvy in 1L triple-negative breast cancer, cell therapy, and more from the oncology pipeline | 05/31/25

08:29

ASCO 2025: Arvinas CEO John Houston discusses the phase 3 study result of the PROTAC Vepdegestrant in breast cancer, the first phase 3 readout of its kind for the field of protein degradation | 06/01/25

11:26

ASCO 2025: Arcus Biosciences' CEO Terry Rosen discusses data for the HIF-2a inhibitor Casdatifan in combination with Cabozantinib in kidney cancer | 06/01/25

11:00

ASCO 2025: Legend Biotech's CEO Ying Huang discusses new CARVYKTI data at ASCO as well as early stage data for emerging CAR-T targets against solid tumors | 06/01/25

12:14

#ASCO25

ApexOnco's Jacob Plieth shares his take on what to watch for at the 2024 ASH Annual meeting | 12/7/24

14:22

Autolus CEO Christian Itin talks about the approval of of the CAR-T Aucatzyl, as well as the company's development pipeline (including autoimmune) | 12/7/24

13:56

ASH 2024: Kite Pharma's global head discusses the progress of the CAR-T field, Arcellx's BCMA data, cures in CD19, autoimmune, and future targets | 12/8/24

13:29

Legend CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more

12:34

ASH 2024: The new CEO of Innate Pharma on taking the job and the company's work on antibodies, engagers, and ADCs | 12/7/24

09:41

ASH 2024: BeiGene CEO John Oyler on degraders, long-term BTK data, BCL2 inhibition, and being a global company | 12/8/24

14:12

ASH 2024: Incyte CEO Hervé Hoppenot on the company's hematology franchise and keeping up the momentum in 2025 | 12/8/24

11:37

Cambridge, UK based CellCentric has a unique approach to targeting p300/CBP and thus reducing the activation of oncogenes like IRF4 and MYC in multiple myeloma | 12/7/24

06:43

#ASH24

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page